• Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis. (wikipedia.org)
  • The significance of tyrosine phosphorylation like a mechanism of signal transduction became widely appreciated using the discovery of varied oncogenes which were themselves tyrosine kinases (PTK) as well as the cloning of receptor tyrosine 76475-17-7 kinases just like the insulin receptor as well as the epidermal growth factor receptor. (biospraysehatalami.com)
  • We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. (biomedcentral.com)
  • We hypothesized that high-dose ESA requirement would be associated with elevated inflammatory biomarkers, decreased adipokines, and increased circulating, endogenous soluble erythropoietin receptors (sEpoR). (nih.gov)
  • This family of receptors shares structural similarities both in their extracellular and intracellular domains and is characterized by the absence of an intrinsic tyrosine kinase. (springer.com)
  • Alexander, W.S . 1999 Thrombopoietin and the c-Mpl receptor: insights from gene targeting. (springer.com)
  • Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. (biomedcentral.com)
  • Based on prior reports on EPO receptor biology, the compounds may also support the treatment of depression and cognitive dysfunction that associate with Parkinson s disease. (michaeljfox.org)
  • Lacombe, C. and Mayeux, P . 1998 Biology of erythropoietin. (springer.com)
  • The primary objective of this work is to determine the optimal time for administration of an erythropoietin (Epo) dose to maximize the erythropoietic effect using a simulation study based on a young sheep pharmacodynamic model. (aspetjournals.org)
  • STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in red blood cell production. (michaeljfox.org)
  • Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. (springer.com)
  • Chronic kidney disease (CKD) blunts erythropoietin production [ 2 ], a proanemic effect that is compounded by other factors such as accelerated erythrocyte destruction and widespread use of concomitant medication such as ACE inhibitors and ARBs [ 3 ]. (hindawi.com)